Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
JMIR Research Protocols|July 11, 2022
The Facilitation of Clinical and Therapeutic Discoveries in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Related Diseases: Protocol for the You + ME Registry Research PlatformAllison Ramiller, Kathleen Mudie, Elle Seibert, et al.
JMIR Research Protocols|October 13, 2022
Correction: The Facilitation of Clinical and Therapeutic Discoveries in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Related Diseases: Protocol for the You + ME Registry Research PlatformAllison Ramiller, Kathleen Mudie, Elle Seibert, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 19, 2014
Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapyLee S Schwartzberg, Mansoor Saleh, Sadie Whittaker, et al.
Frontiers in Neurology|March 28, 2024
Do people with ME/CFS and joint hypermobility represent a disease subgroup? An analysis using registry dataKathleen Mudie, Allison Ramiller, Sadie Whittaker, et al.
Breast Cancer Research and Treatment|June 18, 2013
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative settingGary H Lyman, David C Dale, Dianne Tomita, et al.
Leukemia & Lymphoma|May 1, 2015
Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphomaGary H Lyman, Jeffrey Crawford, Dianne Tomita, et al.
Cancer Medicine|May 10, 2014
Biosimilars 101: considerations for U.S. oncologists in clinical practiceLuis H Camacho, Craig P Frost, Esteban Abella, et al.
Cancer Medicine|March 27, 2015
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Gary H Lyman, David C Dale, Jason C Legg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cellsNoriyuki Takai, Julian C Desmond, Takashi Kumagai, et al.
Cancer|November 3, 2005
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growthNoriyuki Takai, Anjali Jain, Norihiko Kawamata, et al.
Pageof 2